Sunday, November 15, 2026

Sunday Edition: What's Next?

 




Market Talk

Last week, Wall Street saw another round of uncertainty.

Just when the market appeared to be settling down, unforeseen events shook things up again.

One day Goldman Sachs analysts were proclaiming that semiconductors were "oversold".  The very next day, Nvidia (NVDA), the darling of the AI boom, suffered a sudden and possibly temporary fall from grace following the scandal and resignation of CEO Jensen Huang. The fallout raised new questions about leadership and national security involving China. Many chip stocks took it on the chin; others bounced for a day.

Meanwhile, AMD surged as investors looked for alternatives, only to come back down sharply on Friday. Semiconductors stumbled and the Nasdaq lost another 0.9% Friday, although it still managed a gain for the week.

So once again, events that few saw coming shaped investor sentiment and stock prices.

And then there is Washington.

Following the midterm blue wave, new faces in Congress bring more uncertainty. Is America headed for strife or are Americans all fought out?

Hopefully fairness while preserving sovereignty will prevail, along with fiscal responsibility to the taxpaying public.

These are American notions developed from common sense, not notions belonging to any one political party.

And there is another concern that can't be overlooked. Ever-increasing national debt and government spending are not sustainable forever. Look at the troubles in France.

At some point, the cost of servicing our national debt can become an overriding influence on the market.

And that brings us back to investing.  A backdrop of a quarter point  interest rate hike is now expected by the Fed on Dec 9 in response to the higher CPI and a higher jobs number gives them credence to do it.

As far as the overall market, people ponder — What's next? One thing to watch, in the near term, is how the coming Anthropic IPO plays out. Will it revive animal spirits in the AI sector and the overall tech sector?

Stock Talk

After the Test Position — What's Next?

Last week we talked about using smaller "test positions" to get a feel for stocks and gauge the market while preserving dry powder.

But after that, what's next?

Sometimes it may call for trading even small shares, trimming, holding, or even adding shares.

Even beyond keeping in mind fundamentals of growth and earnings prospects. What makes a particular company stand out? What could improve its prospects? And perhaps just as important, where will investor sentiment be heading?

Sometimes adding a few shares on dips makes sense. Other times, adding small tranches even on upticks as investors begin to catch on could be worth considering.

The idea isn't to predict every market turn.

So let's take another look at a few stocks on the Jones List, why they're there, and what might make them outperform, even if the market hasn't caught on yet.

Why Some Are on the Jones List

Gold Miner

KGC — Kinross Gold: A gold producer generating strong cash flow, returning money to shareholders through dividends and buybacks. While concerns about rising costs have corrected the share level from the high 30's down to the low 20's - looking at the earnings reports remain impressive, If KGC were a tech stock or a bitcoin miner - the market would likely be valuing over a $2 eps in the 60's and higher! Is KGC screaming Buy buy buy? Maybe "some" KGC with the way things are is a Jones way of looking at it.

Consumer Stocks — Dividends

KMB — Kimberly-Clark: One of those companies making things people need in good times and bad. With the addition of Kenvue, including brands like Tylenol and Neutrogena, KMB has become an even bigger consumer health business. And it pays a dividend while investors see how the combination works out.


MO — Altria: The tobacco business isn't going away tomorrow, and neither is the attraction of MO's substantial dividend. The company continues to generate cash while expanding into smoke-free products. Here, income is a big part of the attraction. Say what you may but MO has raised dividends consistently over the years and is at a 5.6% rate as of this note.

Semiconductors

NVTS — Navitas Semiconductor: The AI boom requires enormous amounts of electricity, and NVTS makes advanced power semiconductors using GaN and silicon carbide technology to help manage it more efficiently. Its partnership with GFS brings American manufacturing into the picture. Small company, powerful chips.  See the earlier Jones report special edition. The one thing is it's gonna take a little time for earnings to grow positive. But when it starts - watch NVTS.  Until then?  Some is the word we use.

GFS — GlobalFoundries: A U.S.-based semiconductor manufacturer, previously owned by AMD and making its CPUs before AMD sold it off. Now a separate company, GFS still makes some peripheral chips for AMD, along with chips used in everything from refrigerators, RF devices and automobiles to more advanced applications. GFS is also moving into quantum-based chips, photonics and power chips, as pointed out in the Jones Report on NVTS. Domestic chip manufacturing, a global presence and AI infrastructure are a big part of the flair of GFS. America needs GFS as much as GFS needs America to thrive.

LRCX — Lam Research: The machines that help make the chips that make AI possible. Etching and deposition tools are the Lam specialty from this California based company - and they ALL need it. Lam is already generating impressive earnings, and the growing complexity of semiconductor manufacturing could keep demand strong for years. The question isn't whether Lam has a business. It's how much growth the market will price into the shares.

KLAC — KLA Corporation: Another critical player in the semiconductor equipment business, particularly inspection and process control. As chipmakers push technology to smaller dimensions and more complex designs, getting acceptable manufacturing yields becomes critical. That's where KLAC stands out.

Defense

VVX — V2X: A defense contractor that doesn't always get the attention of the big defense names. Yet with a backlog of $12.8 billion and improving earnings, there's plenty of business already on the books. These complicated U. S. fighters and transport military aircraft require a LOT of maintenance and support all around the globe.  VVX has been a consistent and reliable partner with the U.S, and other friendly that depend proper aircraft upkeep.   And VVX being where the action is has proven that they can help rapid prototype and collaborate to provide other defense solutions like The Tempest buggy we saw being deployed in the Youtube from Ukraine.


KTOS — Kratos Defense: Drones, hypersonics and advanced military systems are changing the battlefield. KTOS is involved in these technologies, and recent revenues and orders have been growing sharply. Here at the Jones report, KTOS was originally highlighted in the teens.  The stock rose to over $100 a share and has since faded to the 30's.  The recent adjusted eps of 0.24 points to KTOS very possibly turning the corner.  The drones are quite impressive as illustrated in a prior Jones report. KTOS is a valuable American asset for U.S. defense.


Speculative Biotech

XERS — Xeris Biopharma: With FDA-approved Recorlev for treating Cushing syndrome, XERS has turned profitable on a quarterly basis and raised projections to over $1 billion in total annual revenues by 2030. Recorlev itself could eventually approach a billion dollars annually. That's quite a development for a company that was little noticed by investors not long ago.

CMPS — Compass Pathways: Developing a psilocybin-based treatment for people suffering from treatment-resistant depression. Two successful Phase 3 trials and a completed FDA application bring CMPS closer to a possible new treatment in mental health. If approved, a large unmet medical need could become a substantial market.

HELP — Helus Pharma: Another company pursuing new approaches to depression and anxiety. Its lead treatment has shown promising earlier results, with important Phase 3 data expected before year-end. Here, clinical results could determine whether investors catch on or move on.

INO — Inovio Pharmaceuticals: After years of developing DNA-based medicine, INO finally gained accelerated FDA approval for VOCERYQ to reduce surgeries in patients with recurrent respiratory papillomatosis. Now comes the challenge of turning a scientific achievement into commercial success. The recent stock offering diluted shareholders but supplied badly needed cash.

ONCY — Oncolytics Biotech: Pelareorep has produced some interesting clinical results in cancer treatment, including two complete responses in an earlier anal cancer combination study. But here, the randomized REO 033 colorectal cancer trial and its approaching response data are what matter now. The market has heard the story and it was highlighted here.  Let's see the clinical results.

Anthropic IPO Play

SKM — SK Telecom: A major Korean telecommunications company that made an early $100 million investment in Anthropic, the AI company behind Claude. With Anthropic preparing to go public at an enormous valuation, that early investment has become interesting indeed. This is why SKM is a watch stock, plain and simple reason.

Stay Watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

Sunday, November 8, 2026

Sunday Edition: Market Trades One Uncertainty for Another — and Biotech Corner

 




Market Talk

Market Trades One Uncertainty for Another

Well folks, last week was quite a week on Wall Street.

The day after the November 3 blue wave election sweep, the stock market celebrated with a strong relief rally. But it didn't last long. The very next day, Thursday, November 5, Wall Street suffered a major selloff, with the S&P 500 experiencing its worst one-day decline since the April 2025 tariff turmoil.

And the numbers tell the story.

Wednesday, November 4 — The Relief Rally

  • Dow Jones: UP 1,569 points (+3.0%)

  • S&P 500: UP 1.6%

  • Nasdaq: UP 1.4%

Thursday, November 5 — The Selloff

  • Dow Jones: DOWN 1,833 points (-3.4%)

  • S&P 500: DOWN 4.4%

  • Nasdaq: DOWN 5.5%

In just one trading session, the market wiped out Wednesday's relief rally and then some. The Nasdaq suffered its worst daily decline in 19 months, entering correction territory.

By Friday, November 6, the market seemed to take a breather and return to something resembling normal trading. The Nasdaq recovered 1.1%, the S&P 500 gained 0.3%, while the Dow slipped another 0.5%.

But the tide remained out for many stocks in the aftermath, particularly those associated with artificial intelligence, semiconductors and the massive AI data-center buildout.

So what happened?

It appears Wall Street traded one uncertainty for another.

With the election behind us, investors initially welcomed the prospect of greater political clarity. But that optimism quickly gave way to new concerns about tighter regulation of AI, growing opposition to data-center expansion and whether the enormous amounts of money being poured into AI infrastructure can continue to support lofty stock valuations.

The election uncertainty may be behind us, but the uncertainty of the AI boom is another matter entirely. (But- The AI cat is out of the bag - and our adversaries likely won't slow it). Other uncertainties of war and peace along with social program spending, immigration policy, and tax and spend policies that may become prevalent as inexperienced legislators mistake TDS for a mandate to create ploicies that are against the U.S, constitution. It is doubfful here that Americans want to make the U.S, look like a socialized France that is now undergoing strife and turmoil from failed and "progressive" policy.

Let's Talk Strategy

So, picking up somewhere where we left off last week, let's talk strategy.

The last Jones Report listed some stocks we watch here, each with their own individual dynamics.

Now, we've already highlighted much of what makes these companies stand out, each with its own unique flair for potential outperformance.

But getting there, and the things that happen along the way, are what the market prices in on a daily basis.

Stocks can be as good as the belief in them, as good as their current performance, and as bad as the sentiment of the day.

And that sentiment can shift from darling to dog in a fickle world.

Fundamentals of earnings and growth, along with investor returns, still matter to traditional investors. But there are too many buts to mention here.

And now the political side of things has become even more uncertain.

There are many areas where politics overlaps business. AI data-center growth and regulation in the U.S. is just one example. Even the perception of a changing political tone is having a big negative effect on the technology sector lately.

Stock Talk

When market volatility like last week comes then resides, it's hard to know if the calm is brief like being in the eye of a hurricane.

In short, stocks require watching now if trading. Here, I'm using smaller "test positions" in some stocks.

One thing to notice is the semiconductor tech sector, for example, has herky-jerkily descended, down big one day, bouncing the next but not as much.

It's been like going three steps down a staircase and back up one.

This brings up suspicion of big money putting the shorts on.

When conflating conditions come, a smaller position to preserve buying power can preserve your cash arsenal of trading ammunition — that's dry powder.

One strategy here lately is by having small test positions, it "seems to" help awareness without losing so much skin that human emotion takes over the thinking. I posted the other day, about that. The goal became preserving the better gains of last year when opportunity is clearer.

Now some watch stocks have fallen to interesting levels. That doesn't necessarily mean they are all in full tilt buy situations.

Maybe some, or none till the weather clears.


The following is a list of a few stocks of interest to the Jones Report with recent changing dynamics. There will be more to report on, but these companies have been posted here before and can be found by scrolling through these freely given reports.  If interested in any — remember the tenets here - maybe some, not too much, maybe start with small test positions even one or two shares or 100 shares if a speculative penny stock with big ideas.


Gold and Silver Miners:  KGC, HL and CDE

Consumer stocks (w/dividend):   KMB , CLX,  MO

Semiconductors:   NVTS,  GFS,  LRCX,  KLAC (one or two shares?)

Defense:  VVX ... and back on the watch list — KTOS

Speculative Biotech: XERS, CMPS, HELP, INO, ONCY

Anthropic IPO Play - maybe some SKM


Biotech Corner Notes:

The Biotech sector of healthcare can be an interesting one to follow regardless of the market volatility.  There, individual companies can fly or fail based on their own achievements on bringing new drugs, new treatments to meet the ever-growing needs of human ailment.

As a few notes there was one biopharma that captured interest on the worse day of the market this year. The company XERS was added to the Jones watch list.

Xeris Biopharma Holdings, Inc. (XERS)



XERS management guided higher with somewhat astounding projection of over $1 billion in total annual revenue by 2030, with Recorlev potentially approaching $1 billion itself.

The XERS FDA approved drug to treat Cushing Syndrome. Even as the market cascaded lower, XERS surged a few points higher and it has sustained momentum.  Such demand, if and as it plays out - could be a game changer for XERS stock.


Then we watched Inovio Pharmaceuticals (INO) as accelerated FDA approval was granted of a new DNA based approach to treat HPV related nodules and tumors in the respiratory tract.  Clinical Data shows that significant relief was gained thereby reducing the need for costly surgery. There is an existing shot based on an adapted adenovirus approach that will compete, and both are expensive. Then last week, INO abruptly announced an offering that dilutes shares and at least temporarily quelling the levels. Well, INO needs the cash dearly to take the DNA approach to market.  And the market and perhaps institutions or even bigger Pharma that wants a head start on DNA technology will step up.  For now, the market put INO back under $2 a share.


All the listed biotechs in the Jones list are interesting, with possible catalysts approaching.


Often, stocks under $3 are called "penny stocks". One thing about the Jones report- sometimes we stay aware and open to the possibility and speculation on huge opportunity in stocks under $3 as we saw in the Quantum tech sector last year. However, the other side of the opportunity coin can be peril if not aware of the risk of "too much".  "If and When" speculating - NOT too much - keep it fun and manage expectations along the way.


Long term gain is the notion even when short term pain persists in the market.  

Stay Watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

Wednesday, November 4, 2026

Market Talk — A Relief Rally, But What's Next? The Jones Way FOR NOW (**updated list 11/06)

 




Market Talk

The day after the midterm election presents an interesting day for market and stock watchers. Ancient Chinese curse: May All YOUR Days Be "Interesting". Regardless, today is a relief rally that some uncertainty has been removed. ahhh - but what's next?

As far as politics it's likely to mean daily back-and-forth retributions on TV.  Will that replace productive policies to advance America? Will a proper balance prevail between fiscal restraint and the need to keep America's defense strong against our adversaries and enemies? The possibility of gridlock for the next two years seems to increase.  Many say gridlock is a good thing because it stops morons in government from doing bad things.

The Democrats swept the midterms in a blue tsunami based primarily, it seems, on Trump Derision Syndrome (TDS). The bullshit con artists who are coming in may be worse than the ones going out. That's how this "Independent" views the election cycle — it's usually a choice between the lesser of two evils.

Those from the DSA party gained a foothold at the possible expense of the traditional U.S. Constitution, which has held up for 250 years through thick and thin. It will be up to moderates in both parties to constrain the radicals.

People seem to have lost their thinking minds, unable to separate future policy from their personal dislike of Trump's style. Granted, President Trump was NOT a help in making himself "likable" to many Americans. It actually made him more unpopular.

One thing that really didn't help was his more favorable tone toward Putin and less favorable tone toward Zelensky. WE Americans may think even more highly of Zelensky, and we certainly do NOT like Putin for what he is attempting — taking over Ukraine. And then what's NEXT, Putin? Forget it!

All in all? It looks like more jackasses are asserting themselves these days. NO wonder the people just wanted a change.

Regardless of personal views and party, the general market is responding positively today, except for some sectors involving tech and the typical AI trade. There is also rising concern about the repercussions of AI data-center growth in local communities across America. Meanwhile, some tech, like Apple and Microsoft are bouncing higher. 

If readers have followed the recent posts here, you may not be surprised by my following statement:

I don't give a RAT's ASS what "the market" does.

And why so, Mr. Jones? some readers may ponder ...

Because I have more dry powder than stocks, ready to deploy into companies where I've done enough due diligence (DD) to maintain conviction through the rough patches — adding or subtracting from positions as conditions evolve.

If you follow what is being put down here — read on, friends.

Stock Talk

To save time, the following is a new list of a few stocks of interest to the Jones Report with recent changing dynamics. There will be more to report on, but these companies have been posted here before and can be found by scrolling through these freely given reports.  If interested in any — remember the tenets here - maybe some, not too much, maybe start with small test positions even one or two shares or 100 shares if a speculative penny stock with big ideas.

**Update note 11/06 - Biopharma XERS and defense KTOS added to the watch list on developments and earnings progress.


Gold and Silver Miners:  KGC, HL and CDE

*Consumer stocks (w/dividend):   KMB , CLX,  MO

Semiconductors:   NVTS,  GFS,  LRCX,  KLAC (one or two shares?)

Defense:  VVX ... and back on the watch list — KTOS

**Speculative Biotech: XERS, CMPS, HELP, INO, ONCY

Anthropic IPO Play - maybe some SKM


There are many stocks that the Jones report follows. The above is not an exhaustive list.  The above are watch stocks, not necessarily a buy list.  Regardless of whatever stock you like, either here or elsewhere, perhaps trading with just a few shares to see what comes next - with less pressure on being always right in the near term — is the notion here.

Long term gain is the notion even when short term pain persists in the market.


Stay Watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.

Monday, November 2, 2026

Things Just Changed with New Treatments and FDA Approvals - watching INO and also ... ONCY

 




Breaking News

People are suddenly noticing-something interesting is happening in the biotech sector, and it deserves a closer look.

On October 30, the FDA granted accelerated approval to Inovio Pharmaceuticals (INO) for VOCERYQ, a new DNA-based immunotherapy treating recurrent respiratory papillomatosis (RRP), a rare and serious disease that causes recurring growths in the respiratory tract.

What makes this approval particularly interesting is the relatively small clinical study supporting it.

The study enrolled just 32 patients, with 26 included in the primary efficacy evaluation. Of those 26 patients, seven (27%) achieved a complete response, requiring no additional surgery during the 12 months following treatment.

Think about that.

The FDA granted accelerated approval based on encouraging results from a relatively small study, recognizing the medical needs of patients suffering from a serious disease. A confirmatory study will follow.

Now consider Oncolytics Biotech (ONCY).

ONCY is developing Pelareorep (Pela), an investigational immunotherapy being combined with chemotherapy and bevacizumab, a monoclonal antibody, to treat patients with advanced metastatic colorectal cancer (CRC).

These aren't patients with early-stage cancer. They're patients whose cancer has progressed following initial treatment and who face limited treatment options.

ONCY has already received FDA Fast Track designation for its Pela combination in this patient population.

More importantly, the company has reported FDA feedback supporting a potential accelerated approval pathway based on objective response rates, provided future clinical evidence supports that approach.

Its ongoing randomized REO-033 study is designed to determine whether the encouraging results from the earlier REO-022 trial can be confirmed.

Initial clinical results are anticipated by the end of 2026.

Now here's where things get interesting.

INO just demonstrated that accelerated FDA approval can be achieved with a relatively small clinical study when the evidence supports meaningful treatment benefits for patients with serious unmet medical needs.

ONCY is pursuing a different disease and a different clinical endpoint, but there's an important parallel.

Both are developing innovative immunotherapies for patients with serious diseases who need better treatment options NOW.

INO has already demonstrated a path to FDA approval. ONCY has received FDA feedback supporting a potential accelerated approval pathway, but still needs convincing randomized clinical results.

Hmmmm???? —could ONCY's Pelareorep be approaching a similar opportunity for patients fighting ADVANCED CANCER?

The upcoming REO-033 results should help answer that question.

Now, As Far As Stocks?

Look at INO. The stock closed below $1 on Friday. Following the FDA approval announcement, it surged above $2, with some analysts now setting price targets around $5.

All that excitement in just ONE trading day!

Now look at ONCY, still trading under a buck, with skeptics and shorts banging their tables, impatient for clinical results.

The contrast is striking.

INO's FDA approval changed investor expectations almost overnight. Could positive randomized CRC results eventually produce a similar reassessment of ONCY?

It's a speculative possibility, not a guarantee.

But let's not lose sight of what's really important.

Pelareorep is being developed for patients fighting ADVANCED CANCER, people who NEED some help NOW.

The FDA's accelerated approval pathway exists precisely because certain patients facing serious diseases shouldn't have to wait years for potentially beneficial treatments when credible clinical evidence supports earlier access.

INO has just demonstrated that principle in action.

ONCY still has to deliver the clinical evidence, but the regulatory pathway is already part of the discussion.

In Closing

New immunotherapies and accelerated FDA approval pathways are creating opportunities for patients with serious unmet medical needs, and potentially for investors willing to accept the risks.

INO has just shown how quickly the investment landscape can change following an FDA approval.

Now I'll be watching ONCY's upcoming CRC results with considerable interest.

As this story unfolds, the clinical data and evidence ONCY brings forward will pave the way for what comes next.

Stay Watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.